Kailera Therapeutics (NASDAQ:KLRA) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners started coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a research report issued to clients and investors on Tuesday. The firm set an “outperform” rating and a $36.00 price target on the stock. Leerink Partners’ price objective would indicate a potential upside of 57.00% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the stock. TD Cowen initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set a “buy” rating and a $57.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set a “buy” rating and a $48.00 target price on the stock. William Blair initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating on the stock. Wall Street Zen raised shares of Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. Finally, Evercore initiated coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating on the stock. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Stock Performance

Kailera Therapeutics stock opened at $22.93 on Tuesday. Kailera Therapeutics has a 12 month low of $20.86 and a 12 month high of $28.23.

Insider Transactions at Kailera Therapeutics

In other news, major shareholder Rtw Investments, Lp purchased 500,000 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were purchased at an average price of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the acquisition, the insider owned 10,776,820 shares in the company, valued at $172,429,120. This trade represents a 4.87% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction dated Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the acquisition, the director owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. This trade represents a 47.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 10,460,938 shares of company stock valued at $167,375,008.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.